NEW YORK (GenomeWeb) – Ambry Genetics and Ionis Pharmaceuticals affiliate Akcea Therapeutics have launched a new genetic testing program called hATTR Compass, which will provide no-cost, confidential analyses and genetic counseling to people with suspected hereditary ATTR (hATTR) amyloidosis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.